ibl.ai Agentic AI Blog

Insights on building and deploying agentic AI systems. Our blog covers AI agent architectures, LLM infrastructure, MCP servers, enterprise deployment strategies, and real-world implementation guides. Whether you are a developer building AI agents, a CTO evaluating agentic platforms, or a technical leader driving AI adoption, you will find practical guidance here.

Topics We Cover

Featured Research and Reports

We analyze key research from leading institutions and labs including Google DeepMind, Anthropic, OpenAI, Meta AI, McKinsey, and the World Economic Forum. Our content includes detailed analysis of reports on AI agents, foundation models, and enterprise AI strategy.

For Technical Leaders

CTOs, engineering leads, and AI architects turn to our blog for guidance on agent orchestration, model evaluation, infrastructure planning, and building production-ready AI systems. We provide frameworks for responsible AI deployment that balance capability with safety and reliability.

Back to Blog

Blue Cross Says AI Coding Added $942M to Its Costs. Who Audits the Coder?

ibl.ai EngineeringOctober 1, 2026
Premium

The Blue Cross Blue Shield Association estimated in September 2026 that rising inpatient coding intensity added about $942 million to Blue plan spending between 2023 and 2025, and noted that more than 60% of hospital systems now run AI tools over clinical notes. BCBSA did not prove AI caused it, because claims data cannot show you the reasoning, which is the actual governance problem on both sides of the claim.

The Short Answer

The Blue Cross Blue Shield Association estimated in September 2026 that rising inpatient coding intensity added roughly $942 million to Blue plan spending from 2023 to 2025, and that more than 60% of hospital systems now run AI tools over clinical notes. It did not prove AI caused it, because claims data cannot show the reasoning. On ibl.ai you own all the code and the data, so the reasoning behind each suggested code stays an artifact you can audit.

The analysis was announced in late September 2026. It is a serious piece of work, and the way it travelled is a good illustration of how a careful claims finding turns into a headline that inverts it.

What did Blue Cross Blue Shield actually say about AI medical coding?

It described a divergence between how sick patients are coded and how much treatment the claims show them receiving.

The share of inpatient cases classified as medically complex rose from approximately 37% in early 2023 to 40% by the end of 2025, without the corresponding increase in care that clinical complexity normally brings with it.

About 70% of the incremental cost, more than $650 million, was associated with secondary diagnoses that moved a hospital stay into a higher-severity, higher-paying diagnosis-related group.

The association's September whitepaper, Hospital Coding Intensity Analysis: Major Bowel Procedures, works through more than 55,000 excess complex cases in a single procedure family.

The AI link is an adoption statistic rather than a causal finding: more than 60% of hospital systems now use AI-enabled technology capable of examining clinical notes and records for diagnoses that affect coding.

Did Blue Cross Blue Shield prove AI caused the $942 million?

No, and the association is explicit about it. This is the single most important sentence in the coverage and the one most often dropped.

BCBSA stopped short of proving that artificial intelligence caused each increase. Its analysis relies primarily on claims data rather than complete patient charts, and it identifies no individual hospitals and no AI vendors.

That is not a weakness in the research. It is a description of what claims data can and cannot establish. A claim records the code that was submitted. It does not record why.

The earlier companion analysis, Rising Coding Intensity and Its Impact on Health Care Affordability, found an approximately 9% per-member increase in inpatient costs from 2023 to 2024 across a subset of plans covering about 62 million members, with roughly 20% of that increase attributable to rising coding intensity.

Two consecutive analyses, consistent direction, and in both cases the mechanism is inferred from the output rather than observed in the process.

Who actually paid the $942 million, hospitals or insurers?

The Blue plans did. The $942 million is added spending absorbed by BCBS companies, which flows through to premiums and ultimately to employers and members.

This matters because the widely circulated framing has it as a cost to hospitals. It is the opposite: hospitals received those payments. The payer booked the cost.

Getting that backwards changes who the story is about. A hospital reading "AI billing tools are costing hospitals $942 million" would reasonably conclude the tools are a financial risk to the hospital's own margin.

The real exposure for a hospital is different and arrives later: payer audits, denials, repayment demands, and in the worst case a False Claims Act theory built on a pattern the hospital's own vendor generated.

What does the American Hospital Association say about AI coding intensity?

It disputes the interpretation, and the counterargument is not frivolous.

The AHA's position is that hospitals now care for older and sicker patients, and that AI helps clinicians document legitimate medical complexity that manual coding missed. On that reading, rising complexity codes are a correction rather than an inflation.

The AHA also makes a point that reframes the whole dispute: insurers run their own automated systems to downcode claims in the opposite direction.

So both parties to the claim are running models over the same patient encounter. Each one's model is optimized toward its own revenue position. Neither can inspect the other's.

Why is AI medical coding a governance problem rather than a model problem?

Because the disagreement is about reasoning, and reasoning is the one thing neither side currently has to produce.

A claims-level analysis can show that complexity codes rose faster than treatment intensity. It cannot distinguish a coder catching a documented comorbidity that a human would have missed from a model reaching for a defensible code the clinical picture does not support.

The distinction lives in the chart, the note, and the inference that connected them. That is an artifact, and whether it exists at all is a procurement decision made before the first claim goes out.

Control What goes wrong without it Where it has to live
Note-to-code provenance An audit asks which documentation supported a secondary diagnosis and the answer is a vendor support ticket Your own records, per suggestion
The optimization target A model tuned for capture rate rather than documentation support, set by someone whose revenue depends on capture rate A prompt and policy you can read and change
Human confirmation record No way to show a certified coder reviewed and accepted the suggestion, which is the defense In the workflow, not reconstructed later
Liability alignment The vendor's terms route responsibility to the provider while the vendor keeps control of the model With whoever controls the behavior

The last row is the one that decides the others. A hospital that cannot change the optimization target has accepted the liability for a behavior it cannot adjust.

The in-house alternative and what it takes to run is in AI Medical Coding In-House, and the mirror-image problem on the payer side of the same claim is in Healthcare AI for Revenue Cycle: Prior Authorization and Denials.

Where does ibl.ai fit in a hospital's medical coding stack?

On ibl.ai you own all the code and the data.

The coding assistant, the prompts that define what it optimizes for, the retrieval over your clinical documentation, and the audit log of every suggestion and every human decision all run inside your own perimeter, model-agnostic across any LLM, with no per-seat pricing.

That answers the specific exposure this analysis creates. A health system cannot stop its payers from running downcoding models, and should not expect to.

It can make sure that when a payer audit arrives, the chain from note to code to the coder who approved it is a record it holds rather than an export it has to request.

1.6M+ users across 400+ organizations run the platform this way, including NVIDIA, MIT, and Syracuse University.

The broader version of this question, covering observability across clinical AI rather than coding alone, is in Clinical AI Governance and Observability: Hospitals Own the Stack.

Want a coding stack your health system actually owns?

We deploy clinical documentation and coding agents as source code you keep, with the provenance and audit trail in your own systems, in your cloud, on-premise, or fully air-gapped.

Book a 30-minute demo or talk to the ibl.ai team. ibl.ai is family-owned and operated from New York, NY.

Sources: the $942 million estimate, the 37% to 40% complexity shift, the 70% secondary-diagnosis share and the 60%+ AI adoption figure from BCBSA's September 2026 announcement, reported in the Dallas Express; the 55,000 excess complex cases from BCBSA's Hospital Coding Intensity Analysis whitepaper; the 62 million members, 9% and 20% figures from Rising Coding Intensity and Its Impact on Health Care Affordability; BCBSA's own summaries at New BCBSA Research on AI Hospital Billing; the AHA response as reported in the same coverage.

Why does owning the AI stack matter?

ibl.ai is the agentic AI platform where you own all the code and the data. You self-host the entire stack inside your own perimeter, run it model-agnostic across any LLM and switch anytime, and pay by usage with no per-seat pricing β€” so you can deploy anywhere: your cloud, on-premise, GovCloud, or fully air-gapped.

  • You own all the code and the data

    Full source code under a perpetual license, running on your infrastructure. Not API access to someone else's platform β€” the stack itself is yours.

  • Model-agnostic

    Run any LLM β€” Claude, GPT, Gemini, Llama, Command, or your own fine-tune β€” and switch providers without rewriting the platform.

  • No per-seat pricing

    Usage-based billing against a budget cap you set. Cost tracks what your organization actually uses, not how many people you employ.

  • Deploy anywhere

    Your cloud, your VPC, on-premise, GovCloud, or a fully air-gapped network with no outbound connectivity.

1.6M+ users across 400+ organizations run the platform this way, including NVIDIA, MIT, and Syracuse University.

ibl.ai is family-owned and operated from New York, NY β€” a U.S.-headquartered, domestically-owned long-term partner, not a vendor that sells licenses and moves on.

Related Articles

AI Medical Coding: Why Hospitals Are Bringing It In-House

The economic, clinical, and compliance reasons hospital systems are moving AI medical coding from vendor SaaS to in-house deployment in 2026 β€” and what the right architecture looks like.

Blanca AmigotMay 30, 2026

Hospital AI Aces Single-Turn Tests. Grade the Actions

In Stanford's MedAgentBench, the best overall model completed every one-step EHR task but 23.33% of tasks needing three or more steps, and scored lower on tasks that change a record than on tasks that only read one. A redesigned agent from a team including the original authors later reached 96.67% on its multi-tool-call tasks. Reliability belongs to the agent you deploy, so test it by step count and repeated runs, and gate every write to the record.

ibl.ai EngineeringOctober 9, 2026

PE Firms Put AI Agents in Healthcare. The Data Comes First

Private equity sponsors are putting AI agents into healthcare revenue cycle companies, from R1 under TowerBrook and CD&R to New Mountain's Smarter Technologies. The most specific sponsor-published result we found, Partners Group's 120 bps margin uplift at an insurance brokerage, was built on a clean proprietary dataset, and KPMG lists fragmented, unstructured data among the main bottlenecks. The data is the prerequisite, and who owns it decides what is left at exit.

ibl.ai EngineeringOctober 9, 2026

You Cannot Govern a Clinical Model You Cannot Observe

Anthropic reported that ~950 agents surfaced a novel enzyme system in 21 hours, and the first FDA-approved AI margin-assessment device reached its first operating rooms in August. The capability question is closing. The governance one is not β€” and even that approved device ships AI updates under a change-control plan the hospital does not hold.

ibl.ai EngineeringSeptember 29, 2026

See the ibl.ai AI Operating System in Action

Discover how leading universities and organizations are transforming education with the ibl.ai AI Operating System. Explore real-world implementations from Harvard, MIT, Stanford, and users from 400+ institutions worldwide.

View Case Studies
Work with our team

Pilots, deployment, and full ownership

Most enterprise engagements are one-time, not subscriptions. You integrate ibl.ai with your own data, deploy it on your own infrastructure, and the engineering hours scale with the work β€” so the price tracks the scope, not your headcount.

Start here

Pilot

from $15K

fixed scope Β· fixed timeline

A time-boxed proof of value on your real data β€” not a slide deck.

Best for: Teams that want to see ibl.ai working before committing.

  • Deployed on your infrastructure or our cloud
  • 1–2 production agents wired to a slice of your data
  • One integration (LMS / SIS / SSO / data source)
  • Weekly working sessions with our engineers
  • Pilot fee credits toward a full engagement
Scope a pilot
Most common

Integration & Deployment

$25K – $80K

one-time Β· not a subscription

Full deployment integrated with your data and systems. Engineering hours scale with scope.

Best for: Organizations rolling ibl.ai out across a department, campus, or business unit.

  • Platform deployed in your VPC, on-prem, or air-gapped
  • Integrated with your data + identity (SSO / SAML)
  • Multiple custom agents built to your workflows
  • Engineering hours proportional to scope
  • You own the data Β· run any LLM you choose
Plan a deployment
Full ownership

Codebase Transfer + Custom AI Engineering

Custom quote

perpetual license Β· you own the stack

We transfer the full source code. You own and self-host the entire platform β€” outright.

Best for: Organizations and enterprises that benefit from perpetual ownership and sovereignty.

  • Complete source-code transfer + perpetual license
  • Dedicated AI engineering team on your roadmap
  • Custom agents, models, and integrations to spec
  • Air-gapped capable Β· zero vendor lock-in
  • Family-owned, New York–based long-term partner
Talk about ownership
You own the code and data Run any LLM β€” Claude, GPT, Gemini, Llama Family-owned & operated from New York, NY